NCT07435480

Brief Summary

Study the relation between irisin level and progression of diabetic nephropathy and its early detection.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
19mo left

Started Apr 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
Apr 2026Mar 2028

First Submitted

Initial submission to the registry

February 20, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 27, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2028

Last Updated

March 10, 2026

Status Verified

February 1, 2026

Enrollment Period

11 months

First QC Date

February 20, 2026

Last Update Submit

March 7, 2026

Conditions

Diabetic Nephropathies

Outcome Measures

Primary Outcomes (1)

  • Measure number of Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).

    Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).

    Two years

Interventions

HBa1cDIAGNOSTIC_TEST

Rapid method for detection of diabetes

glucoseDIAGNOSTIC_TEST

accurate method for diabetes

Eligibility Criteria

Age30 Years - 75 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Type 2 diabetic patients between 30-75 years old

You may qualify if:

  • Type 2 diabetic patients

You may not qualify if:

  • Non-diabetic kidney diseases.
  • Acute illness, infection, obesity, hypertension, type 1 DM.
  • Malignancy, other endocrine disorders, corticosteroid drugs, pregnancy, lactation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetic Nephropathies

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System Diseases

Study Officials

  • Ahmed Se Mahmoud, ass prof

    Sohag University

    STUDY DIRECTOR

Central Study Contacts

Gehad Ha Abdelmegid, MD

CONTACT

00201125745717gege1_8_1992@yahoo.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Target Duration
2 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle investigator

Study Record Dates

First Submitted

February 20, 2026

First Posted

February 27, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 1, 2028

Last Updated

March 10, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share